Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevacizumab + FOLFIRI in Metastatic Colorectal Cancer
NCT02453464Phase 1Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Aug 2015
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suvemcitug in metastatic colorectal cancer (mCRC), sponsored by Simcere Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose up to 56 days. Status: unknown.
02
Drugs
suvemcitug
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02453464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02453464.